metformin has been researched along with Diabetic Angiopathies in 190 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 9.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| "To investigate the preventive action of metformin for atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM)." | 9.14 | [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus]. ( Ba, Y; Bai, R; Du, JL; Jia, YJ; Men, LL; Xing, Q; Yang, Y; Zhang, XY, 2009) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 9.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "Type 2 diabetes mellitus (T2DM) patients have a lower risk of abdominal aortic aneurysm (AAA) and its comorbidities, which might be associated with the usage of metformin." | 9.12 | The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis. ( Cai, Z; Heng, Z; Lu, Y; Wei, J; Yuan, Z, 2021) |
| "To investigate the effects of metformin on glycemic control, insulin resistance, and risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups (Caucasian and Asian) with different risks of cardiovascular disease." | 9.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| "There is an ongoing controversy regarding the safety and effectiveness of metformin in the setting of heart failure (HF)." | 8.89 | Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. ( Eurich, DT; Johnson, JA; Majumdar, SR; McAlister, FA; Tjosvold, L; Tsuyuki, RT; Vanderloo, SE; Weir, DL, 2013) |
| "To evaluate the association between metformin use and heart failure (HF) exacerbation in people with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models." | 7.88 | Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. ( Abrahamowicz, M; Beauchamp, ME; Eurich, DT; Weir, DL, 2018) |
| "We conducted a population-based case-control study to assess the myocardial infarction (MI) and stroke risks associated with sulphonylureas and insulin when used in combination with metformin." | 7.81 | Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. ( Dublin, S; Flory, JH; Floyd, JS; Heckbert, SR; Psaty, BM; Sitlani, CM; Smith, NL; Wiggins, KL, 2015) |
| "Despite the limitations of this observational study, diabetes patients with MS who were treated with metformin plus DPP-4 inhibitors had better compliance, greater metabolic control, and lower rates of hypoglycemia, causing lower costs for the Spanish national health system than patients receiving metformin plus other antidiabetes drugs." | 7.80 | Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. ( Navarro-Artieda, R; Sicras-Mainar, A, 2014) |
| "Aim of the study was to clarify the relationship between metformin-induced vitamin B12 (B12) deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes." | 7.79 | Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. ( Aizawa, T; Funase, Y; Ouchi, K; Sato, Y; Yamauchi, K, 2013) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 7.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 6.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "<6." | 5.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "Metformin is a kind of oral hypoglycemic agents commonly prescribed to patients with diabetes mellitus." | 5.40 | Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. ( Chen, CL; Chen, TJ; Cheng, YY; Kao, CL; Kuo, CH; Lee, SD; Leu, HB, 2014) |
| "Metformin was associated with a reduced risk of CHF (HR 0." | 5.35 | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. ( Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS, 2009) |
| "All-cause mortality, cardiovascular death, cardiovascular events (death, hospitalization for heart failure, myocardial infarction, stroke or myocardial ischemia), end stage renal disease (ESRD) and the kidney disease composite (ESRD or death) were compared in metformin users and non-users with diabetes and CKD enrolled in the Trial to Reduce Cardiovascular Events with Aranesp (darbepoeitin-alfa) Therapy (TREAT) (NCT00093015)." | 5.30 | Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. ( Burdmann, EA; Charytan, DM; Claggett, B; Cooper, ME; Eckardt, KU; Ivanovich, P; Levey, AS; Lewis, EF; Liu, J; McGill, JB; McMurray, JJV; Parfrey, P; Parving, HH; Pfeffer, MA; Remuzzi, G; Singh, AK; Solomon, SD; Weinrauch, LA, 2019) |
| "In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months." | 5.22 | Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. ( Ala-Korpela, M; Holman, RR; Kangas, AJ; Preiss, D; Rankin, N; Sattar, N; Soininen, P; Welsh, P; Würtz, P, 2016) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 5.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 5.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "To investigate the preventive action of metformin for atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM)." | 5.14 | [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus]. ( Ba, Y; Bai, R; Du, JL; Jia, YJ; Men, LL; Xing, Q; Yang, Y; Zhang, XY, 2009) |
| "Metformin treatment prevented weight gain (mean weight gain, -3." | 5.14 | Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. ( Bets, D; de Jager, J; Donker, AJ; Kooy, A; Lehert, P; Stehouwer, CD; Wulffelé, MG, 2009) |
| "Type 2 diabetes mellitus (T2DM) patients have a lower risk of abdominal aortic aneurysm (AAA) and its comorbidities, which might be associated with the usage of metformin." | 5.12 | The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis. ( Cai, Z; Heng, Z; Lu, Y; Wei, J; Yuan, Z, 2021) |
| " The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been reported." | 5.09 | Improved endothelial function with metformin in type 2 diabetes mellitus. ( Anderson, TJ; Mather, KJ; Verma, S, 2001) |
| "The BIGuanides and Prevention of Risks in Obesity (BIGPRO1) results suggest that metformin would be a suitable candidate for long-term intervention for the prevention of diabetes but that its use in a trial of primary prevention of cardiovascular diseases requires either a reevaluation of its properties toward the most potentially atherogenic anomalies of the IRS or a better definition of the target population." | 5.08 | The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. ( André, P; Bard, JM; Charles, MA; Cohen, JM; Eschwège, E; Fontbonne, A; Grandmottet, P; Isnard, F; Juhan-Vague, I; Safar, ME; Vague, P, 1996) |
| "To investigate the effects of metformin on glycemic control, insulin resistance, and risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups (Caucasian and Asian) with different risks of cardiovascular disease." | 5.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| "There is an ongoing controversy regarding the safety and effectiveness of metformin in the setting of heart failure (HF)." | 4.89 | Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. ( Eurich, DT; Johnson, JA; Majumdar, SR; McAlister, FA; Tjosvold, L; Tsuyuki, RT; Vanderloo, SE; Weir, DL, 2013) |
| "7% as monotherapy or in combination with metformin (MET), sulfonylureas (SFU), and/or thiazolidinediones (TZD); with mean weight losses of -1." | 4.89 | Evolution of exenatide as a diabetes therapeutic. ( Bhavsar, S; Cherrington, A; Mudaliar, S, 2013) |
| "The UK Prospective Diabetes Study showed that metformin decreases mortality compared to diet alone in overweight patients with type 2 diabetes mellitus." | 4.88 | Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. ( Bejan-Angoulvant, T; Boissel, JP; Boussageon, R; Cornu, C; Cucherat, M; Gueyffier, F; Kassai, B; Kellou, N; Moreau, A; Supper, I, 2012) |
| " For metformin, the United Kingdom Prospective Diabetes Study (UKPDS) substudy is convincing for a definite effect in reducing myocardial infarction (MI), but the quantitative extent of that is uncertain." | 4.88 | Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes. ( Home, P, 2012) |
| "The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance." | 4.83 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " Metformin and renin-angiotensin system blockers were negatively associated with albuminuria and chronic kidney disease stages (p < 0." | 4.02 | Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. ( Abdulraheem, AM; Abufaraj, M; Al-Sabbagh, MQ; Albtoosh, A; Aljabiri, H; Arabiat, M; Farah, RI; Momani, MS, 2021) |
| "To evaluate the association between metformin use and heart failure (HF) exacerbation in people with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models." | 3.88 | Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. ( Abrahamowicz, M; Beauchamp, ME; Eurich, DT; Weir, DL, 2018) |
| "All Danish individuals using dual therapy with SU + insulin or metformin + insulin without prior myocardial infarction (MI) or stroke were followed from 1 January 1997 to 31 December 2009 in nationwide registries." | 3.81 | Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| "In intention-to-treat analyses, there was no difference in the risk of any cardiovascular event among the add-on combination treatment groups, but significantly lower risks of acute myocardial infarction were found for the glinides plus metformin treatment group (crude hazard ratio 0." | 3.81 | Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. ( Chang, CH; Chang, YC; Chen, ST; Chuang, LM; Lai, MS; Lin, JW, 2015) |
| "We conducted a population-based case-control study to assess the myocardial infarction (MI) and stroke risks associated with sulphonylureas and insulin when used in combination with metformin." | 3.81 | Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. ( Dublin, S; Flory, JH; Floyd, JS; Heckbert, SR; Psaty, BM; Sitlani, CM; Smith, NL; Wiggins, KL, 2015) |
| "Despite the limitations of this observational study, diabetes patients with MS who were treated with metformin plus DPP-4 inhibitors had better compliance, greater metabolic control, and lower rates of hypoglycemia, causing lower costs for the Spanish national health system than patients receiving metformin plus other antidiabetes drugs." | 3.80 | Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. ( Navarro-Artieda, R; Sicras-Mainar, A, 2014) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| " All-cause mortality and a composite endpoint of stroke, acute myocardial infarction (AMI) and all-cause mortality associated with sitagliptin monotherapy were compared with metformin monotherapy." | 3.80 | All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population. ( Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A, 2014) |
| "Aim of the study was to clarify the relationship between metformin-induced vitamin B12 (B12) deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes." | 3.79 | Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. ( Aizawa, T; Funase, Y; Ouchi, K; Sato, Y; Yamauchi, K, 2013) |
| "In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective." | 3.73 | Determinants of subclinical diabetic heart disease. ( Downey, M; Fang, ZY; Marwick, TH; Prins, J; Schull-Meade, R, 2005) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 3.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "The Treatment Options for type 2 Diabetes in Adolescent and Youth study, a randomized clinical trial of three treatments for type 2 diabetes (T2DM) in youth, demonstrated treatment failure (defined as sustained HbA1c ≥8%, or inability to wean insulin after 3 months after acute metabolic decomposition) in over half of the participants." | 2.94 | Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study. ( Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM, 2020) |
| "Youth with type 1 diabetes (T1D) carry greater cardiovascular disease (CVD) risk than their nondiabetic peers." | 2.90 | Serum uromodulin inversely associates with aortic stiffness in youth with type 1 diabetes: A brief report from EMERALD study. ( Baumgartner, A; Bjornstad, P; Coe, G; Cree-Green, M; Johnson, RJ; Nadeau, KJ; Pyle, L; Reyes, YG; Roncal, C; Schäfer, M; Truong, U; Wiromrat, P, 2019) |
| "Twenty-six patients with type 2 diabetes were randomized to a 12 week of high intensity interval training (3 sessions/week) or standard care control group." | 2.90 | High intensity interval training protects the heart during increased metabolic demand in patients with type 2 diabetes: a randomised controlled trial. ( Cassidy, S; Grbovic, M; Jakovljevic, DG; MacGowan, GG; Ninkovic, V; Okwose, N; Popovic, D; Suryanegara, J; Trenell, MI, 2019) |
| "Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis." | 2.84 | Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial. ( Anderson, JJA; Coppin, B; Couper, JJ; Gent, R; Giles, LC; Leggett, CE; Peña, AS, 2017) |
| " The most common adverse events with exenatide QWS-AI were gastrointestinal events and injection-site reactions." | 2.84 | Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. ( Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML, 2017) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 2.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "People with insulin-requiring type 2 diabetes and high cardiovascular risk were enrolled during a run-in period on basal-bolus insulin (BBI), and 102 were randomized to continued BBI or to basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN) group, each seeking to maintain HbA(1c) levels between 6." | 2.80 | Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. ( Bergenstal, R; Branch, KR; Davis, B; Hirsch, I; Khakpour, D; Kingry, C; O'Brien, K; Pressel, S; Probstfield, JL; Riddle, M, 2015) |
| "Metformin is an antidiabetic drug with beneficial cardiovascular disease effects in diabetes." | 2.79 | Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes. ( Argraves, WS; Cangemi, C; Christensen, MM; Gram, J; Grodum, E; Henriksen, JE; Rasmussen, LM; Skov, V; Sørensen, D, 2014) |
| " Pharmacodynamic parameters were assessed at baseline and at weeks 1 and 12." | 2.79 | Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. ( Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS, 2014) |
| "Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control." | 2.73 | 10-year follow-up of intensive glucose control in type 2 diabetes. ( Bethel, MA; Holman, RR; Matthews, DR; Neil, HA; Paul, SK, 2008) |
| "In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation." | 2.73 | Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. ( Frandsen, M; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K, 2008) |
| "Five RCTs including 50,725 type 2 diabetes patients, of whom 10,013 had not received metformin, were included in this meta-analysis." | 2.72 | SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. ( Barrios, V; Cosín, J; Escobar, C; Gámez Martínez, JM; Huelmos Rodrigo, AI; Martínez Zapata, MJ; Ortíz Cortés, C; Requeijo, C; Solà, I; Torres Llergo, J, 2021) |
| " Diabetics showed blunted dose-response curves to both SNP and ACh." | 2.71 | Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. ( Baldeweg, S; Baldi, S; Casolaro, A; Ferrannini, E; Natali, A; Sironi, AM; Toschi, E; Yudkin, JS, 2005) |
| "Troglitazone therapy was associated with increases in LDL size (26." | 2.70 | Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. ( Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R, 2002) |
| "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks." | 2.69 | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. ( , 1998) |
| "Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our understanding of the underlying pathophysiologic defects has evolved." | 2.55 | Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. ( Thrasher, J, 2017) |
| "Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD)-namely myocardial infarction, heart failure, and stroke." | 2.55 | Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. ( Lüscher, TF; Paneni, F, 2017) |
| "Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD)-namely myocardial infarction, heart failure, and stroke." | 2.55 | Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. ( Lüscher, TF; Paneni, F, 2017) |
| "Antidiabetic drugs for type 2 diabetes receive marketing authorization if they show efficacy in reducing levels of HbA(1c)." | 2.50 | Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence? ( Boussageon, R; Cornu, C; Gueyffier, F, 2014) |
| "Metformin has unique, intrinsic actions specifically at the level of terminal arterioles, which are completely independent of its antidiabetic effect." | 2.48 | Microvascular diseases: is a new era coming? ( Rapin, JR; Wiernsperger, N, 2012) |
| "Metformin is a biguanide, insulin sensitiser that reduces blood sugar levels." | 2.46 | Metformin: safety in cardiac patients. ( Khurana, R; Malik, IS, 2010) |
| " Acarbose has a very good safety profile and, owing to its straightforward, non-systemic mode of action, avoids most adverse events." | 2.44 | Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. ( Hanefeld, M, 2007) |
| "Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity." | 2.44 | Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. ( Carvalho, C; Correia, S; Moreira, PI; Oliveira, CR; Santos, MS; Seiça, R, 2008) |
| "Metformin has long been known to reduce the development of atherosclerotic lesions in animal models, and clinical studies have shown the drug to reduce surrogate measures such as carotid intima-media thickness." | 2.44 | Metformin: effects on micro and macrovascular complications in type 2 diabetes. ( Bailey, CJ, 2008) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | 2.42 | Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
| "Nateglinide was well tolerated with a low incidence of hypoglycemia in all subgroups, including those with RI and low baseline HbA(1c)." | 2.42 | Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. ( Del Prato, S; Emmons, RP; Guitard, C; Heine, RJ; Keilson, L; Shen, SG, 2003) |
| "Patients with type 2 diabetes have an increased risk for cardiovascular disease (CVD) and it accounts for up to 80% of excess deaths in these patients." | 2.42 | Role of oral anti-diabetic agents in modifying cardiovascular risk factors. ( Farag, A; McFarlane, SI; Rothman, J; Shin, JJ; Sowers, JR, 2003) |
| "Treatment with metformin reduced mortality due to cardiovascular disease in obese patients." | 2.40 | [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications]. ( Heine, RJ; Wolffenbuttel, BH, 1999) |
| "Management of patients with type 2 diabetes should focus on decreasing the excess macrovascular disease with which it is associated as well as preventing or minimizing microvascular disease." | 2.40 | Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. ( Lebovitz, HE, 1999) |
| "Metformin is a sage and effective drug for management of non-insulin-dependent diabetes mellitus." | 2.40 | Metformin. ( Bell, PM; Hadden, DR, 1997) |
| "<6." | 1.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "The global incidence and prevalence of type 2 diabetes have been escalating in recent decades." | 1.56 | 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. ( Chang, KC; Chao, TF; Chao, TH; Chen, WJ; Cheng, HM; Cheng, SM; Chiang, CE; Chu, PH; Huang, JL; Hung, HF; Hwang, JJ; Lai, WT; Li, YH; Lin, SJ; Lin, TH; Liu, ME; Liu, PY; Shyu, KG; Sung, SH; Tsai, CD; Ueng, KC; Wang, KL; Wu, YJ; Wu, YW; Yeh, HI; Yeh, SJ; Yin, WH, 2020) |
| " The relatively high GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin." | 1.51 | Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study. ( Dove, F; Gates, PE; Goncalves, I; Gooding, K; Khan, F; Looker, HC; Natali, A; Nesti, L; Nilsson, J; Persson, M; Shore, AC; Venturi, E, 2019) |
| "Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0." | 1.46 | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. ( Aubert, CE; Bourron, O; Cluzel, P; Hartemann, A; Kamel, S; Kemel, S; Lalau, JD; Lenglet, A; Liabeuf, S; Mary, A; Massy, ZA; Mentaverri, R; Salem, JE, 2017) |
| "469 ambulatory type 2 diabetes patients (mean diabetes duration 10." | 1.46 | Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. ( Fleischer, J; Hansen, CS; Jensen, JS; Jørgensen, ME; Ridderstråle, M; Vistisen, D, 2017) |
| " Given that lowering glucose is the first objective of diabetic patients, we also examined the effects of SAA combined with metformin (MET) on both complications." | 1.43 | Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury. ( Du, GH; He, YY; Hou, BY; Ma, LL; Niu, ZR; Pang, XC; Song, JK; Wu, P; Yan, Y; Yang, XY; Zhang, L, 2016) |
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| "63) and nine times less likely to adhere to their medications if they received more than once daily dosing of diabetic medication (OR = 0." | 1.40 | Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes. ( Almrayat, R; Alqudah, S; Jarab, AS; Khdour, M; Mukattash, TL; Pinto, S; Thehairat, E, 2014) |
| "Metformin treatment prevented weight gain ((315." | 1.40 | Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats. ( Gui, Q; Tan, Z; Wu, W; Xu, Z; Yang, Y, 2014) |
| "Metformin is a kind of oral hypoglycemic agents commonly prescribed to patients with diabetes mellitus." | 1.40 | Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. ( Chen, CL; Chen, TJ; Cheng, YY; Kao, CL; Kuo, CH; Lee, SD; Leu, HB, 2014) |
| "A cohort of 32 871 patients with Type 2 diabetes aged 35 years and older identified by extracting data from electronic patient records for all patients who had a diagnosis of Type 2 diabetes and had glucose-lowering agents prescribed between 1999 and 2009 at 84 primary care centres in Sweden." | 1.39 | Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. ( Johansson, G; Lohm, L; Nilsson, PM; Östgren, CJ; Sundström, J; Svennblad, B, 2013) |
| "Metformin was independently associated with lower prevalence of cardiovascular disease for any age quartile and eGFR category than all other treatments." | 1.39 | Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. ( Bonora, E; Cavalot, F; Cignarelli, M; Ferrannini, E; Fondelli, C; Morano, S; Orsi, E; Penno, G; Pugliese, G; Solini, A; Trevisan, R; Vedovato, M, 2013) |
| "Metformin was administered to all patients for 16 weeks." | 1.36 | Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. ( Chen, LL; Hu, LJ; Li, YM; Liao, YF; Zeng, TS, 2010) |
| "In 1998 and 1999, 1,353 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the Netherlands." | 1.36 | Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. ( Bilo, HJ; Gans, RO; Groenier, KH; Kleefstra, N; Landman, GW; van Hateren, KJ, 2010) |
| "Metformin was associated with a reduced risk of CHF (HR 0." | 1.35 | The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. ( Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS, 2009) |
| "Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride." | 1.35 | Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. ( Mogensen, CE; Sadikot, SM, 2008) |
| "Pioglitazone was associated with reduced all cause mortality compared with metformin." | 1.35 | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. ( Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR, 2009) |
| "Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0." | 1.34 | Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. ( Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH, 2007) |
| "Pretreatment with metformin also decreased phosphorylation of Akt and protein kinase C (PKC) in ECs under these conditions." | 1.33 | Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. ( Gerdes, N; Isoda, K; Libby, P; MacFarlane, LA; Schönbeck, U; Tsuboi, N; Young, JL; Zirlik, A, 2006) |
| "Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0." | 1.33 | Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. ( Johnson, JA; Majumdar, SR; Simpson, SH; Toth, EL, 2005) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | 1.32 | Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. ( Abrahamson, MJ, 2004) |
| " Specifically, dose-response experiments of acetylcholine (ACh) with or without N-nitro-L-arginine (LNNA) were performed." | 1.31 | Metformin improves vascular function in insulin-resistant rats. ( Hoenig, M; Katakam, PV; Miller, AW; Ujhelyi, MR, 2000) |
| "We aimed to examine the survival in NIDDM patients with IHD using various types of oral antidiabetic treatments over a 5-year follow-up period." | 1.30 | Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. ( Behar, S; Benderly, M; Fisman, EZ; Goldbourt, U; Motro, M; Tenenbaum, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (2.63) | 18.7374 |
| 1990's | 20 (10.53) | 18.2507 |
| 2000's | 71 (37.37) | 29.6817 |
| 2010's | 87 (45.79) | 24.3611 |
| 2020's | 7 (3.68) | 2.80 |
| Authors | Studies |
|---|---|
| Tryggestad, JB | 1 |
| Shah, RD | 1 |
| Braffett, BH | 1 |
| Bacha, F | 2 |
| Gidding, SS | 2 |
| Gubitosi-Klug, RA | 1 |
| Shah, AS | 1 |
| Urbina, EM | 1 |
| Levitt Katz, LE | 1 |
| Chiang, CE | 1 |
| Ueng, KC | 1 |
| Chao, TH | 1 |
| Lin, TH | 1 |
| Wu, YJ | 1 |
| Wang, KL | 1 |
| Sung, SH | 1 |
| Yeh, HI | 1 |
| Li, YH | 1 |
| Liu, PY | 1 |
| Chang, KC | 1 |
| Shyu, KG | 1 |
| Huang, JL | 1 |
| Tsai, CD | 1 |
| Hung, HF | 1 |
| Liu, ME | 1 |
| Chao, TF | 1 |
| Cheng, SM | 1 |
| Cheng, HM | 1 |
| Chu, PH | 1 |
| Yin, WH | 1 |
| Wu, YW | 1 |
| Chen, WJ | 1 |
| Lai, WT | 1 |
| Lin, SJ | 1 |
| Yeh, SJ | 1 |
| Hwang, JJ | 1 |
| Crowley, MJ | 1 |
| McGuire, DK | 3 |
| Alexopoulos, AS | 1 |
| Jensen, TJ | 1 |
| Rasmussen, S | 1 |
| Saevereid, HA | 1 |
| Verma, S | 2 |
| Buse, JB | 1 |
| Davidson, MB | 1 |
| Escobar, C | 1 |
| Barrios, V | 1 |
| Cosín, J | 1 |
| Gámez Martínez, JM | 1 |
| Huelmos Rodrigo, AI | 1 |
| Ortíz Cortés, C | 1 |
| Torres Llergo, J | 1 |
| Requeijo, C | 1 |
| Solà, I | 1 |
| Martínez Zapata, MJ | 1 |
| Farah, RI | 1 |
| Al-Sabbagh, MQ | 1 |
| Momani, MS | 1 |
| Albtoosh, A | 1 |
| Arabiat, M | 1 |
| Abdulraheem, AM | 1 |
| Aljabiri, H | 1 |
| Abufaraj, M | 1 |
| Yuan, Z | 1 |
| Heng, Z | 1 |
| Lu, Y | 1 |
| Wei, J | 1 |
| Cai, Z | 1 |
| Paneni, F | 2 |
| Lüscher, TF | 2 |
| Thrasher, J | 1 |
| Dell'Oro, R | 1 |
| Maloberti, A | 1 |
| Nicoli, F | 1 |
| Villa, P | 1 |
| Gamba, P | 1 |
| Bombelli, M | 1 |
| Mancia, G | 1 |
| Grassi, G | 1 |
| Yandrapalli, S | 1 |
| Jolly, G | 1 |
| Horblitt, A | 1 |
| Sanaani, A | 1 |
| Aronow, WS | 1 |
| Perreault, L | 1 |
| Pan, Q | 1 |
| Aroda, VR | 1 |
| Barrett-Connor, E | 3 |
| Dabelea, D | 1 |
| Dagogo-Jack, S | 1 |
| Hamman, RF | 1 |
| Kahn, SE | 1 |
| Mather, KJ | 4 |
| Knowler, WC | 1 |
| Anderson, JJA | 1 |
| Couper, JJ | 1 |
| Giles, LC | 1 |
| Leggett, CE | 1 |
| Gent, R | 1 |
| Coppin, B | 1 |
| Peña, AS | 1 |
| Raz, I | 2 |
| Mosenzon, O | 2 |
| Bonaca, MP | 1 |
| Cahn, A | 1 |
| Kato, ET | 1 |
| Silverman, MG | 1 |
| Bhatt, DL | 1 |
| Leiter, LA | 1 |
| Wilding, JPH | 1 |
| Gause-Nilsson, IAM | 1 |
| Langkilde, AM | 1 |
| Johansson, PA | 1 |
| Sabatine, MS | 1 |
| Wiviott, SD | 1 |
| Lupsa, BC | 1 |
| Inzucchi, SE | 2 |
| Weir, DL | 2 |
| Abrahamowicz, M | 1 |
| Beauchamp, ME | 1 |
| Eurich, DT | 2 |
| Natali, A | 2 |
| Nesti, L | 1 |
| Venturi, E | 1 |
| Shore, AC | 1 |
| Khan, F | 1 |
| Gooding, K | 1 |
| Gates, PE | 1 |
| Looker, HC | 1 |
| Dove, F | 1 |
| Goncalves, I | 1 |
| Persson, M | 1 |
| Nilsson, J | 1 |
| Bain, SC | 1 |
| Arechavaleta, R | 1 |
| Bogdański, P | 1 |
| Comlekci, A | 1 |
| Consoli, A | 1 |
| Deerochanawong, C | 1 |
| Dungan, K | 1 |
| Faingold, MC | 1 |
| Farkouh, ME | 1 |
| Franco, DR | 1 |
| Gram, J | 3 |
| Guja, C | 1 |
| Joshi, P | 1 |
| Malek, R | 1 |
| Merino-Torres, JF | 1 |
| Nauck, MA | 1 |
| Pedersen, SD | 1 |
| Sheu, WH | 1 |
| Silver, RJ | 1 |
| Tack, CJ | 1 |
| Tandon, N | 1 |
| Jeppesen, OK | 1 |
| Strange, M | 1 |
| Thomsen, M | 1 |
| Husain, M | 1 |
| Powell, WR | 1 |
| Christiansen, CL | 1 |
| Miller, DR | 1 |
| Ahmed, FW | 1 |
| Bakhashab, S | 1 |
| Bastaman, IT | 1 |
| Crossland, RE | 1 |
| Glanville, M | 1 |
| Weaver, JU | 1 |
| Suryanegara, J | 1 |
| Cassidy, S | 1 |
| Ninkovic, V | 1 |
| Popovic, D | 1 |
| Grbovic, M | 1 |
| Okwose, N | 1 |
| Trenell, MI | 1 |
| MacGowan, GG | 1 |
| Jakovljevic, DG | 1 |
| Niu, C | 1 |
| Chen, Z | 1 |
| Kim, KT | 1 |
| Sun, J | 1 |
| Xue, M | 1 |
| Chen, G | 1 |
| Li, S | 1 |
| Shen, Y | 1 |
| Zhu, Z | 1 |
| Wang, X | 1 |
| Liang, J | 1 |
| Jiang, C | 1 |
| Cong, W | 1 |
| Jin, L | 1 |
| Li, X | 1 |
| Charytan, DM | 1 |
| Solomon, SD | 1 |
| Ivanovich, P | 1 |
| Remuzzi, G | 1 |
| Cooper, ME | 1 |
| McGill, JB | 1 |
| Parving, HH | 2 |
| Parfrey, P | 1 |
| Singh, AK | 1 |
| Burdmann, EA | 1 |
| Levey, AS | 1 |
| Eckardt, KU | 1 |
| McMurray, JJV | 1 |
| Weinrauch, LA | 1 |
| Liu, J | 1 |
| Claggett, B | 1 |
| Lewis, EF | 1 |
| Pfeffer, MA | 1 |
| Wiromrat, P | 1 |
| Bjornstad, P | 1 |
| Roncal, C | 1 |
| Cree-Green, M | 1 |
| Baumgartner, A | 1 |
| Coe, G | 1 |
| Reyes, YG | 1 |
| Schäfer, M | 1 |
| Truong, U | 1 |
| Pyle, L | 2 |
| Johnson, RJ | 1 |
| Nadeau, KJ | 1 |
| El Messaoudi, S | 1 |
| Rongen, GA | 1 |
| Riksen, NP | 1 |
| Hopkins, ND | 1 |
| Cuthbertson, DJ | 1 |
| Kemp, GJ | 1 |
| Pugh, C | 1 |
| Green, DJ | 1 |
| Cable, NT | 1 |
| Jones, H | 1 |
| Majumdar, SR | 2 |
| Tsuyuki, RT | 1 |
| Johnson, JA | 2 |
| Tjosvold, L | 1 |
| Vanderloo, SE | 1 |
| McAlister, FA | 1 |
| Bhatt, MP | 1 |
| Lim, YC | 1 |
| Kim, YM | 1 |
| Ha, KS | 1 |
| Solini, A | 1 |
| Penno, G | 3 |
| Bonora, E | 1 |
| Fondelli, C | 1 |
| Orsi, E | 1 |
| Trevisan, R | 1 |
| Vedovato, M | 1 |
| Cavalot, F | 1 |
| Cignarelli, M | 1 |
| Morano, S | 1 |
| Ferrannini, E | 3 |
| Pugliese, G | 1 |
| Sato, Y | 1 |
| Ouchi, K | 1 |
| Funase, Y | 1 |
| Yamauchi, K | 1 |
| Aizawa, T | 1 |
| Scheller, NM | 2 |
| Mogensen, UM | 2 |
| Andersson, C | 2 |
| Vaag, A | 4 |
| Torp-Pedersen, C | 3 |
| Cao, X | 1 |
| Li, H | 2 |
| Tao, H | 1 |
| Wu, N | 1 |
| Yu, L | 1 |
| Zhang, D | 1 |
| Lu, X | 1 |
| Zhu, J | 1 |
| Lu, Z | 1 |
| Zhu, Q | 1 |
| Florez, H | 1 |
| Temprosa, MG | 1 |
| Orchard, TJ | 3 |
| Marcovina, SM | 2 |
| Horton, E | 1 |
| Saudek, C | 2 |
| Pi-Sunyer, XF | 1 |
| Ratner, RE | 3 |
| Goldberg, RB | 3 |
| Cheng, YY | 1 |
| Leu, HB | 1 |
| Chen, TJ | 1 |
| Chen, CL | 1 |
| Kuo, CH | 1 |
| Lee, SD | 1 |
| Kao, CL | 1 |
| Garg, SK | 1 |
| Michels, AW | 1 |
| Shah, VN | 1 |
| Skov, V | 1 |
| Cangemi, C | 1 |
| Christensen, MM | 1 |
| Grodum, E | 1 |
| Sørensen, D | 1 |
| Argraves, WS | 1 |
| Henriksen, JE | 1 |
| Rasmussen, LM | 1 |
| Guénette, L | 1 |
| Breton, MC | 1 |
| Hamdi, H | 1 |
| Grégoire, JP | 1 |
| Moisan, J | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 2 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Levitt Katz, L | 1 |
| Hirst, K | 1 |
| McKay, S | 1 |
| Lima, JA | 1 |
| Boussageon, R | 2 |
| Gueyffier, F | 2 |
| Cornu, C | 2 |
| Tan, Z | 1 |
| Xu, Z | 1 |
| Gui, Q | 1 |
| Wu, W | 1 |
| Yang, Y | 2 |
| Miles, JM | 1 |
| Rule, AD | 1 |
| Borlaug, BA | 1 |
| Jarab, AS | 1 |
| Almrayat, R | 1 |
| Alqudah, S | 1 |
| Thehairat, E | 1 |
| Mukattash, TL | 1 |
| Khdour, M | 1 |
| Pinto, S | 1 |
| Sha, S | 1 |
| Polidori, D | 1 |
| Heise, T | 1 |
| Natarajan, J | 1 |
| Farrell, K | 1 |
| Wang, SS | 1 |
| Sica, D | 1 |
| Rothenberg, P | 1 |
| Plum-Mörschel, L | 1 |
| Zhang, Y | 1 |
| Hu, C | 1 |
| Hong, J | 1 |
| Zeng, J | 1 |
| Lai, S | 1 |
| Lv, A | 1 |
| Su, Q | 1 |
| Dong, Y | 1 |
| Zhou, Z | 1 |
| Tang, W | 1 |
| Zhao, J | 1 |
| Cui, L | 1 |
| Zou, D | 1 |
| Wang, D | 1 |
| Liu, C | 1 |
| Wu, G | 1 |
| Shen, J | 1 |
| Zhu, D | 1 |
| Wang, W | 1 |
| Shen, W | 1 |
| Ning, G | 1 |
| Xu, G | 1 |
| Sicras-Mainar, A | 1 |
| Navarro-Artieda, R | 1 |
| Konrad, K | 1 |
| Datz, N | 1 |
| Engelsberger, I | 1 |
| Grulich-Henn, J | 1 |
| Hoertenhuber, T | 1 |
| Knauth, B | 1 |
| Meissner, T | 1 |
| Wiegand, S | 1 |
| Woelfle, J | 1 |
| Holl, RW | 1 |
| Fosbøl, EL | 2 |
| Schramm, TK | 2 |
| Gislason, G | 1 |
| Køber, L | 2 |
| Li, T | 1 |
| Yang, GM | 1 |
| Zhu, Y | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Kruszelnicka, O | 1 |
| Chyrchel, B | 1 |
| Golay, A | 1 |
| Surdacki, A | 1 |
| Wang, J | 1 |
| Ciaraldi, TP | 1 |
| Samad, F | 1 |
| Chang, YC | 1 |
| Chuang, LM | 1 |
| Lin, JW | 1 |
| Chen, ST | 1 |
| Lai, MS | 1 |
| Chang, CH | 1 |
| DeFronzo, RA | 2 |
| Probstfield, JL | 1 |
| Hirsch, I | 1 |
| O'Brien, K | 1 |
| Davis, B | 1 |
| Bergenstal, R | 1 |
| Kingry, C | 1 |
| Khakpour, D | 1 |
| Pressel, S | 1 |
| Branch, KR | 1 |
| Riddle, M | 1 |
| Zonszein, J | 1 |
| Lombardero, M | 1 |
| Ismail-Beigi, F | 1 |
| Palumbo, P | 1 |
| Foucher, S | 1 |
| Groenewoud, Y | 1 |
| Cushing, G | 1 |
| Wajchenberg, B | 1 |
| Genuth, S | 1 |
| Floyd, JS | 1 |
| Wiggins, KL | 1 |
| Sitlani, CM | 1 |
| Flory, JH | 1 |
| Dublin, S | 1 |
| Smith, NL | 1 |
| Heckbert, SR | 1 |
| Psaty, BM | 1 |
| Xu, T | 1 |
| Brandmaier, S | 1 |
| Messias, AC | 1 |
| Herder, C | 1 |
| Draisma, HH | 1 |
| Demirkan, A | 1 |
| Yu, Z | 1 |
| Ried, JS | 1 |
| Haller, T | 1 |
| Heier, M | 1 |
| Campillos, M | 1 |
| Fobo, G | 1 |
| Stark, R | 1 |
| Holzapfel, C | 1 |
| Adam, J | 1 |
| Chi, S | 1 |
| Rotter, M | 1 |
| Panni, T | 1 |
| Quante, AS | 1 |
| He, Y | 1 |
| Prehn, C | 1 |
| Roemisch-Margl, W | 1 |
| Kastenmüller, G | 1 |
| Willemsen, G | 1 |
| Pool, R | 1 |
| Kasa, K | 1 |
| van Dijk, KW | 1 |
| Hankemeier, T | 1 |
| Meisinger, C | 1 |
| Thorand, B | 1 |
| Ruepp, A | 1 |
| Hrabé de Angelis, M | 1 |
| Li, Y | 2 |
| Wichmann, HE | 1 |
| Stratmann, B | 1 |
| Strauch, K | 1 |
| Metspalu, A | 1 |
| Gieger, C | 1 |
| Suhre, K | 1 |
| Adamski, J | 1 |
| Illig, T | 1 |
| Rathmann, W | 1 |
| Roden, M | 1 |
| Peters, A | 1 |
| van Duijn, CM | 1 |
| Boomsma, DI | 1 |
| Meitinger, T | 1 |
| Wang-Sattler, R | 1 |
| Malin, SK | 1 |
| Braun, B | 1 |
| Preiss, D | 1 |
| Rankin, N | 1 |
| Welsh, P | 1 |
| Holman, RR | 5 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Würtz, P | 1 |
| Ala-Korpela, M | 1 |
| Sattar, N | 1 |
| Wang, LP | 1 |
| Jiang, Y | 1 |
| Yang, H | 1 |
| Peng, C | 1 |
| Zhang, C | 1 |
| Tao, X | 1 |
| Xie, HH | 1 |
| Prentice, JC | 1 |
| Pizer, SD | 1 |
| Conlin, PR | 1 |
| Wu, P | 1 |
| Yan, Y | 1 |
| Ma, LL | 1 |
| Hou, BY | 1 |
| He, YY | 1 |
| Zhang, L | 1 |
| Niu, ZR | 1 |
| Song, JK | 1 |
| Pang, XC | 1 |
| Yang, XY | 1 |
| Du, GH | 1 |
| Hansen, CS | 1 |
| Jensen, JS | 1 |
| Ridderstråle, M | 1 |
| Vistisen, D | 1 |
| Jørgensen, ME | 1 |
| Fleischer, J | 1 |
| Qaseem, A | 1 |
| Barry, MJ | 1 |
| Humphrey, LL | 1 |
| Forciea, MA | 1 |
| Fitterman, N | 1 |
| Horwitch, C | 1 |
| Kansagara, D | 1 |
| McLean, RM | 1 |
| Wilt, TJ | 1 |
| Jax, T | 1 |
| Stirban, A | 1 |
| Terjung, A | 1 |
| Esmaeili, H | 1 |
| Berk, A | 1 |
| Thiemann, S | 1 |
| Chilton, R | 1 |
| von Eynatten, M | 1 |
| Marx, N | 1 |
| Mary, A | 1 |
| Hartemann, A | 1 |
| Liabeuf, S | 1 |
| Aubert, CE | 1 |
| Kemel, S | 1 |
| Salem, JE | 1 |
| Cluzel, P | 1 |
| Lenglet, A | 1 |
| Massy, ZA | 1 |
| Lalau, JD | 1 |
| Mentaverri, R | 1 |
| Bourron, O | 1 |
| Kamel, S | 1 |
| Gadde, KM | 1 |
| Vetter, ML | 1 |
| Iqbal, N | 1 |
| Öhman, P | 1 |
| Nikkanen, T | 1 |
| Timonen, M | 1 |
| Ylitalo, K | 1 |
| Timonen, O | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Rajala, U | 1 |
| Paul, SK | 1 |
| Bethel, MA | 1 |
| Matthews, DR | 1 |
| Neil, HA | 1 |
| Hermansen, K | 1 |
| Mortensen, LS | 1 |
| Hermansen, ML | 1 |
| Sadikot, SM | 1 |
| Mogensen, CE | 1 |
| Correia, S | 1 |
| Carvalho, C | 1 |
| Santos, MS | 1 |
| Seiça, R | 1 |
| Oliveira, CR | 1 |
| Moreira, PI | 1 |
| Scheen, AJ | 1 |
| Paquot, N | 1 |
| Lefebvre, PJ | 1 |
| Duckworth, W | 1 |
| Abraira, C | 1 |
| Moritz, T | 1 |
| Reda, D | 1 |
| Emanuele, N | 1 |
| Reaven, PD | 2 |
| Zieve, FJ | 1 |
| Marks, J | 1 |
| Davis, SN | 1 |
| Hayward, R | 1 |
| Warren, SR | 1 |
| Goldman, S | 1 |
| McCarren, M | 1 |
| Vitek, ME | 1 |
| Henderson, WG | 1 |
| Huang, GD | 1 |
| Temprosa, M | 2 |
| Haffner, S | 1 |
| Fowler, SE | 2 |
| Mather, K | 1 |
| Marcovina, S | 1 |
| Matulik, MJ | 1 |
| Price, D | 1 |
| O'Connor, PJ | 1 |
| Sperl-Hillen, JM | 1 |
| Johnson, PE | 1 |
| Rush, WA | 1 |
| Asche, SE | 1 |
| Dutta, P | 1 |
| Biltz, GR | 1 |
| Pantalone, KM | 1 |
| Kattan, MW | 1 |
| Yu, C | 1 |
| Wells, BJ | 1 |
| Arrigain, S | 1 |
| Jain, A | 1 |
| Atreja, A | 1 |
| Zimmerman, RS | 1 |
| Kittisupamongkol, W | 1 |
| Kooy, A | 1 |
| de Jager, J | 1 |
| Lehert, P | 1 |
| Bets, D | 1 |
| Wulffelé, MG | 1 |
| Donker, AJ | 1 |
| Stehouwer, CD | 2 |
| Hemmingsen, B | 1 |
| Lund, SS | 2 |
| Pruski, M | 1 |
| Krysiak, R | 1 |
| Okopien, B | 1 |
| Del Prato, S | 3 |
| Miccoli, R | 2 |
| Kassem, SA | 1 |
| Bianchi, C | 1 |
| Daniele, G | 1 |
| Heller, SR | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| van Hateren, KJ | 1 |
| Groenier, KH | 1 |
| Gans, RO | 1 |
| Bilo, HJ | 1 |
| Tzoulaki, I | 1 |
| Molokhia, M | 1 |
| Curcin, V | 1 |
| Little, MP | 1 |
| Millett, CJ | 1 |
| Ng, A | 1 |
| Hughes, RI | 1 |
| Khunti, K | 1 |
| Wilkins, MR | 1 |
| Majeed, A | 1 |
| Elliott, P | 1 |
| Zhang, XY | 1 |
| Du, JL | 1 |
| Jia, YJ | 1 |
| Bai, R | 1 |
| Ba, Y | 1 |
| Xing, Q | 1 |
| Men, LL | 1 |
| Monte, SV | 1 |
| Schentag, JJ | 1 |
| Adelman, MH | 1 |
| Paladino, JA | 1 |
| Liao, YF | 1 |
| Chen, LL | 1 |
| Zeng, TS | 1 |
| Li, YM | 1 |
| Hu, LJ | 1 |
| Khurana, R | 1 |
| Malik, IS | 1 |
| Sillars, B | 1 |
| Davis, WA | 1 |
| Hirsch, IB | 1 |
| Davis, TM | 1 |
| Corrao, G | 1 |
| Romio, SA | 1 |
| Zambon, A | 1 |
| Merlino, L | 1 |
| Bosi, E | 1 |
| Scavini, M | 1 |
| Lamanna, C | 1 |
| Monami, M | 2 |
| Marchionni, N | 1 |
| Mannucci, E | 1 |
| Esposito, K | 1 |
| Maiorino, MI | 1 |
| Di Palo, C | 1 |
| Gicchino, M | 1 |
| Petrizzo, M | 1 |
| Bellastella, G | 1 |
| Saccomanno, F | 1 |
| Giugliano, D | 1 |
| Joya-Galeana, J | 1 |
| Fernandez, M | 1 |
| Cervera, A | 1 |
| Reyna, S | 1 |
| Ghosh, S | 1 |
| Triplitt, C | 1 |
| Musi, N | 1 |
| Cersosimo, E | 1 |
| Gislason, GH | 1 |
| Rasmussen, JN | 1 |
| Folke, F | 1 |
| Hansen, ML | 1 |
| Norgaard, ML | 1 |
| Madsen, M | 1 |
| Hansen, PR | 1 |
| Gore, MO | 1 |
| Sullivan, SD | 1 |
| Umans, JG | 1 |
| Ratner, R | 1 |
| Villena, JE | 1 |
| Yoshiyama, CA | 1 |
| Sánchez, JE | 1 |
| Hilario, NL | 1 |
| Merin, LM | 1 |
| Ragia, G | 1 |
| Manolopoulos, VG | 1 |
| Ekström, N | 1 |
| Miftaraj, M | 1 |
| Svensson, AM | 1 |
| Andersson Sundell, K | 1 |
| Cederholm, J | 1 |
| Zethelius, B | 1 |
| Gudbjörnsdottir, S | 1 |
| Eliasson, B | 1 |
| Jarnert, C | 1 |
| Kalani, M | 1 |
| Rydén, L | 3 |
| Böhm, F | 1 |
| Wiernsperger, N | 3 |
| Rapin, JR | 1 |
| Supper, I | 1 |
| Bejan-Angoulvant, T | 1 |
| Kellou, N | 1 |
| Cucherat, M | 1 |
| Boissel, JP | 1 |
| Kassai, B | 1 |
| Moreau, A | 1 |
| Kuritzky, L | 1 |
| Home, P | 1 |
| Klempfner, R | 1 |
| Leor, J | 1 |
| Tenenbaum, A | 3 |
| Fisman, EZ | 3 |
| Goldenberg, I | 1 |
| Montez, M | 1 |
| Saudek, CD | 1 |
| Sherif, H | 1 |
| Watson, KE | 1 |
| Bergenstal, RM | 1 |
| Porter, TK | 1 |
| Weaver, C | 1 |
| Han, J | 2 |
| Bhavsar, S | 1 |
| Mudaliar, S | 1 |
| Cherrington, A | 1 |
| Östgren, CJ | 1 |
| Sundström, J | 1 |
| Svennblad, B | 1 |
| Lohm, L | 1 |
| Nilsson, PM | 1 |
| Johansson, G | 1 |
| Muniyappa, R | 1 |
| El-Atat, F | 1 |
| Aneja, A | 1 |
| McFarlane, SI | 2 |
| Heine, RJ | 2 |
| Keilson, L | 1 |
| Guitard, C | 1 |
| Shen, SG | 1 |
| Emmons, RP | 1 |
| Chu, JW | 1 |
| Abbasi, F | 1 |
| McLaughlin, TL | 1 |
| Lamendola, C | 1 |
| Schaaf, P | 1 |
| Carlson, TH | 1 |
| Leary, ET | 1 |
| Reaven, GM | 1 |
| Wiernsperger, NF | 1 |
| Bouskela, E | 2 |
| Shin, JJ | 1 |
| Rothman, J | 1 |
| Farag, A | 1 |
| Sowers, JR | 1 |
| Abrahamson, MJ | 1 |
| Kao, J | 1 |
| Tobis, J | 1 |
| McClelland, RL | 1 |
| Heaton, MR | 1 |
| Davis, BR | 1 |
| Holmes, DR | 1 |
| Currier, JW | 1 |
| Dandona, P | 1 |
| Aljada, A | 1 |
| Chaudhuri, A | 1 |
| Mohanty, P | 1 |
| Belcher, G | 1 |
| Lambert, C | 1 |
| Goh, KL | 1 |
| Edwards, G | 1 |
| Valbuena, M | 1 |
| von Bibra, H | 1 |
| Hansen, A | 1 |
| Dounis, V | 1 |
| Bystedt, T | 1 |
| Malmberg, K | 2 |
| Maru, S | 1 |
| Koch, GG | 1 |
| Stender, M | 1 |
| Clark, D | 1 |
| Gibowski, L | 1 |
| Petri, H | 1 |
| White, AD | 1 |
| Simpson, RJ | 1 |
| Fang, ZY | 1 |
| Schull-Meade, R | 1 |
| Downey, M | 1 |
| Prins, J | 1 |
| Marwick, TH | 1 |
| Toschi, E | 1 |
| Baldeweg, S | 1 |
| Casolaro, A | 1 |
| Baldi, S | 1 |
| Sironi, AM | 1 |
| Yudkin, JS | 2 |
| Jawa, AA | 1 |
| Fonseca, VA | 2 |
| Masoudi, FA | 1 |
| Wang, Y | 1 |
| Havranek, EP | 1 |
| Foody, JM | 1 |
| Krumholz, HM | 1 |
| Simpson, SH | 1 |
| Toth, EL | 1 |
| Isoda, K | 1 |
| Young, JL | 1 |
| Zirlik, A | 1 |
| MacFarlane, LA | 1 |
| Tsuboi, N | 1 |
| Gerdes, N | 1 |
| Schönbeck, U | 1 |
| Libby, P | 1 |
| Evans, JM | 1 |
| Ogston, SA | 1 |
| Emslie-Smith, A | 1 |
| Morris, AD | 1 |
| Blonde, L | 1 |
| Klein, EJ | 1 |
| Zhang, B | 1 |
| Mac, SM | 1 |
| Poon, TH | 1 |
| Taylor, KL | 1 |
| Trautmann, ME | 1 |
| Kim, DD | 2 |
| Kendall, DM | 1 |
| Pfützner, A | 1 |
| Schneider, CA | 1 |
| Forst, T | 1 |
| Schindler, TH | 1 |
| Facta, AD | 1 |
| Prior, JO | 1 |
| Cadenas, J | 1 |
| Hsueh, WA | 1 |
| Quinones, MJ | 1 |
| Schelbert, HR | 1 |
| Tayek, JA | 1 |
| Tamura, H | 1 |
| Mokuno, H | 1 |
| Daita, H | 1 |
| Kraemer de Aguiar, LG | 1 |
| Laflor, CM | 1 |
| Bahia, L | 1 |
| Villela, NR | 1 |
| Bottino, DA | 1 |
| Stocker, DJ | 1 |
| Taylor, AJ | 1 |
| Langley, RW | 1 |
| Jezior, MR | 1 |
| Vigersky, RA | 1 |
| Raccah, D | 1 |
| Heikkinen, M | 1 |
| Salmenperä, M | 1 |
| Lepäntalo, A | 1 |
| Lepäntalo, M | 1 |
| Hanefeld, M | 1 |
| Anselmino, M | 1 |
| Ohrvik, J | 1 |
| Standl, E | 2 |
| Schnell, O | 1 |
| Motro, M | 2 |
| Bailey, CJ | 1 |
| Traynor, K | 1 |
| Herrington, WG | 1 |
| Levy, JB | 1 |
| Tarnow, L | 1 |
| Schalkwijk, CG | 1 |
| Teerlink, T | 1 |
| Winther, K | 1 |
| Frandsen, M | 1 |
| Smidt, UM | 1 |
| Pedersen, O | 1 |
| Vaag, AA | 1 |
| Rao, AD | 1 |
| Kuhadiya, N | 1 |
| Reynolds, K | 1 |
| Baraldi, B | 1 |
| Maestri, G | 1 |
| Cusimano, A | 1 |
| Valenti, C | 1 |
| Tiraboschi, L | 1 |
| Cocuzza, E | 1 |
| Angeli, G | 1 |
| Sgambato, S | 1 |
| Varricchio, M | 1 |
| Tesauro, P | 1 |
| Passariello, N | 1 |
| Carbone, L | 1 |
| Schernthaner, G | 1 |
| Nagi, DK | 1 |
| Turner, RC | 3 |
| Grant, PJ | 2 |
| Fontbonne, A | 1 |
| Charles, MA | 1 |
| Juhan-Vague, I | 1 |
| Bard, JM | 1 |
| André, P | 3 |
| Isnard, F | 4 |
| Cohen, JM | 1 |
| Grandmottet, P | 1 |
| Vague, P | 1 |
| Safar, ME | 1 |
| Eschwège, E | 1 |
| Katayama, S | 1 |
| Bell, PM | 1 |
| Hadden, DR | 1 |
| Piccolo, I | 1 |
| Sterzi, R | 1 |
| Thiella, G | 1 |
| Lebovitz, HE | 1 |
| Wolffenbuttel, BH | 1 |
| Holstein, A | 1 |
| Nahrwold, D | 1 |
| Hinze, S | 1 |
| Egberts, EH | 1 |
| Benderly, M | 1 |
| Goldbourt, U | 1 |
| Behar, S | 1 |
| Zimmet, P | 1 |
| Collier, G | 1 |
| Katakam, PV | 1 |
| Ujhelyi, MR | 1 |
| Hoenig, M | 1 |
| Miller, AW | 1 |
| Buysschaert, M | 2 |
| Hermans, MP | 2 |
| Basin, C | 1 |
| Greenfield, JR | 1 |
| Chisholm, DJ | 1 |
| Dramais, AS | 1 |
| Wallemacq, PE | 1 |
| Nagai, T | 1 |
| Tomizawa, T | 1 |
| Tonooka, N | 1 |
| Mita, Y | 1 |
| Misumi, S | 1 |
| Mori, M | 1 |
| Anderson, TJ | 1 |
| Marcus, AO | 1 |
| Standeven, KF | 1 |
| Ariëns, RA | 1 |
| Whitaker, P | 1 |
| Ashcroft, AE | 1 |
| Weisel, JW | 1 |
| Chu, NV | 1 |
| Kong, AP | 1 |
| Armstrong, D | 1 |
| Baxi, S | 1 |
| Deutsch, R | 1 |
| Caulfield, M | 1 |
| Mudaliar, SR | 1 |
| Reitz, R | 1 |
| Henry, RR | 1 |
| Christiansen, AL | 1 |
| Madsbad, S | 1 |
| Cho, YW | 1 |
| Yang, DH | 1 |
| Oh, DY | 1 |
| Baick, SH | 1 |
| Kim, SK | 1 |
| Kim, SJ | 1 |
| Hong, SY | 1 |
| Ibagnez, A | 1 |
| Peacock, I | 1 |
| Hawkins, M | 1 |
| Heptinstall, S | 1 |
| Kenworthy, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events[NCT01179048] | Phase 3 | 9,341 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes[NCT02692716] | Phase 3 | 3,183 participants (Actual) | Interventional | 2017-01-17 | Completed | ||
| Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial[NCT02318446] | Phase 3 | 36 participants (Anticipated) | Interventional | 2015-03-31 | Not yet recruiting | ||
| A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study[NCT04231838] | 576 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| South Danish Diabetes Study: A Prospective Randomised Multi-Centre Study for the Evaluation of the Optimal Pharmacological Antidiabetic Treatment of Type 2 Diabetes Mellitus[NCT00121966] | Phase 4 | 400 participants | Interventional | 2003-01-31 | Completed | ||
| Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes[NCT03132181] | Phase 2 | 40 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Comparison of Metformin Hydrochloride Sustained-release Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes[NCT03039075] | Phase 4 | 240 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Role of Synchronized Lifestyle Modification Program on Diabetic Peripheral Neuropathy Patients Taking Oral Hypoglycemics and GLP-1 Analogues[NCT04813146] | 216 participants (Anticipated) | Interventional | 2021-02-05 | Recruiting | |||
| Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')[NCT01703286] | Phase 1 | 42 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus[NCT01652729] | Phase 3 | 365 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)[NCT02384265] | 41 participants (Actual) | Interventional | 2012-06-21 | Completed | |||
| A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity[NCT04101669] | 240 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572] | 200 participants (Anticipated) | Observational | 2012-01-31 | Active, not recruiting | |||
| Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin[NCT02026310] | 40 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| The Study to Investigate the Contribution of Basal and Post-prandial Blood Glucose to Overall Glycaemia in Subjects With Normal Glycaemic Metabolism and Type 2 Diabetes[NCT02648685] | 337 participants (Actual) | Observational | 2015-11-30 | Completed | |||
| A Randomized Trial of Care Navigator to Support Younger Latinx Adults Newly Diagnosed With Type 2 Diabetes (AURORA)[NCT05754008] | 204 participants (Anticipated) | Interventional | 2023-03-31 | Recruiting | |||
| Dietary Fiber in Nutritional Therapy for Chronic Diseases[NCT04690075] | 120 participants (Anticipated) | Interventional | 2020-12-24 | Recruiting | |||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily[NCT01310452] | 50 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | |||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin[NCT03455985] | 158 participants (Actual) | Interventional | 2018-05-01 | Completed | |||
| A Prospective, Randomized, Controlled Study on Self-monitoring of Blood Glucose (SMBG) Protocols in Predicting Glucose Levels in Senior Patients With Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)[NCT01954771] | 89 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)[NCT00032487] | Phase 3 | 1,791 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| SimCare: Physician Intervention to Improve Diabetes Care[NCT00262704] | 2,020 participants (Actual) | Interventional | 2001-12-31 | Completed | |||
| Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial[NCT00375388] | Phase 3 | 400 participants | Interventional | 1998-01-31 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| The Emirates Heart Health Project: A Stepped-wedge Cluster Randomized-controlled Trial of a Family-based Health Coach Guided Dietary and Exercise Intervention for Reducing Weight and Cardiovascular Risk in Overweight and Obese Adult Nationals of the Unite[NCT04688684] | 80 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | |||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Glucose Lowering Drug Treatment in Primary Care[NCT01121315] | 58,326 participants (Actual) | Observational | 2010-05-31 | Completed | |||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes.[NCT00747409] | Phase 4 | 120 participants (Anticipated) | Interventional | 2004-07-31 | Active, not recruiting | ||
| Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study[NCT01004757] | 41 participants (Anticipated) | Interventional | 2008-02-29 | Active, not recruiting | |||
| An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus[NCT00111540] | Phase 3 | 456 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes[NCT02694575] | 241 participants (Actual) | Observational | 2015-03-01 | Completed | |||
| A Pilot Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes[NCT05514080] | 10 participants (Actual) | Interventional | 2019-12-06 | Completed | |||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The TELE-DD Project: a Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Comorbid Depression[NCT04097483] | 428 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb[NCT04625985] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-14 | Completed | ||
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Time from randomisation to first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure. The percentage of subjects experiencing first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 20.3 |
| Placebo | 22.7 |
Time from randomisation to all cause death. The percentage of subjects with a death by any cause (all-cause death) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 8.2 |
| Placebo | 9.6 |
"Time from randomisation to first occurrence of a composite microvascular outcome, defined as any one of the following:~new onset of persistent macroalbuminuria~persistent doubling of serum creatinine~need for continuous renal replacement therapy~death due to renal disease~need for retinal photocoagulation or treatment with intravitreal agents~vitreous haemorrhage~diabetes-related blindness~The percentage of subjects experiencing a first occurrence of a composite microvascular outcome is presented." (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Liraglutide | 7.6 |
| Placebo | 8.9 |
Time from randomisation to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome). The percentage of subjects experiencing a first event of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) |
|---|---|
| Liraglutide | 13.0 |
| Placebo | 14.9 |
Time from randomisation to each individual component of the composite microvascular outcome and to the retinopathy and nephropathy composite outcomes separately. The percentage of subjects experiencing each individual component of the composite microvascular outcome are presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | Percentage of subjects (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nephropathy composite | New onset of persistent macroalbuminuria | Persistent doubling of serum creatinine | Need for continuous renal-replacement therapy | Death due to renal disease | Retinopathy composite | Treatment with photocoagulation/intravitreal agent | Development of diabetes-related blindness | Vitreous haemorrhage | |
| Liraglutide | 5.7 | 3.4 | 1.9 | 1.2 | 0.2 | 2.3 | 2.1 | 0.0 | 0.7 |
| Placebo | 7.2 | 4.6 | 2.1 | 1.4 | 0.1 | 2.0 | 1.8 | 0.02 | 0.5 |
Time from randomisation to each individual component of the expanded composite cardiovascular outcome. The percentage of subjects experiencing each of the individual component of the expanded composite cardiovascular outcome (defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or heart failure) is presented. (NCT01179048)
Timeframe: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
| Intervention | percentage of subjects (Number) | |||||
|---|---|---|---|---|---|---|
| Cardiovascular death | Non-fatal stroke | Non-fatal myocardial infarction | Unstable angina pectoris (hospitalisation) | Coronary revascularisation | Heart failure (hospitalisation) | |
| Liraglutide | 4.7 | 3.4 | 6.0 | 2.6 | 8.7 | 4.7 |
| Placebo | 6.0 | 3.8 | 6.8 | 2.7 | 9.4 | 5.3 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Change from baseline (week 0) in body weight measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Kg (Mean) |
|---|---|
| Oral Semaglutide | -4.2 |
| Placebo | -0.8 |
Change from baseline (week 0) in HbA1c measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Percentage of HbA1c (Mean) |
|---|---|
| Oral Semaglutide | -1.0 |
| Placebo | -0.3 |
Change from baseline (week 0) in HDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Ratio of HDL-cholesterol (Geometric Mean) |
|---|---|
| Oral Semaglutide | 1.05 |
| Placebo | 1.02 |
Change from baseline (week 0) in LDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Ratio of LDL-cholesterol (Geometric Mean) |
|---|---|
| Oral Semaglutide | 0.96 |
| Placebo | 0.97 |
Change from baseline (week 0) in pulse rate measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window). (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Beats/minute (Mean) |
|---|---|
| Oral Semaglutide | 4 |
| Placebo | -0 |
Change from baseline (week 0) in total cholesterol (mmol/L) at the end of treatment (week 83) visit is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Ratio of total cholesterol (Geometric Mean) |
|---|---|
| Oral Semaglutide | 0.97 |
| Placebo | 0.98 |
Change from baseline (week 0) in triglycerides (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | Ratio of triglycerides (Geometric Mean) |
|---|---|
| Oral Semaglutide | 0.92 |
| Placebo | 0.97 |
Number of serious adverse events were recorded from week 0 to week 87 in the study. Results are based on the on-treatment observation period which started at the date of first dose on trial product and ended on last date on trial product +38 days (ascertainment window). (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window.
| Intervention | Events (Number) |
|---|---|
| Oral Semaglutide | 545 |
| Placebo | 618 |
Number of all-cause deaths in the study are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 23 |
| Placebo | 45 |
Participants experiencing first occurrence of a composite CV endpoint (defined as all-cause death, non-fatal myocardial infarction or nonfatal stroke) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 69 |
| Placebo | 89 |
Number of participants experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 61 |
| Placebo | 76 |
Participants experiencing first occurrence of an expanded composite CV endpoint [defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, UAP (unstable angina pectoris) requiring hospitalisation or heart failure requiring hospitalisation] are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 83 |
| Placebo | 100 |
Number of participants experiencing a first event of a fatal or non-fatal myocardial infarction are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 37 |
| Placebo | 35 |
Number of participants experiencing a first event of a fatal or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 13 |
| Placebo | 17 |
Number of participants who permanently discontinued trial product in ths study are presented. Results are based on the on-treatment observation period which starts at the date of first dose on trial product; ends on last date on trial product +38 days (ascertainment window). (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is expected to be no longer than 19 months + 38 days of ascertainment window.
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide | 184 |
| Placebo | 104 |
Participants with eye examination findings, normal, abnormal non clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -3) and end of treatment visit (week 83) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Week -3, End of treatment
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Left eye fundoscopy (week -3): Normal | Left eye fundoscopy (week -3): Abnormal NCS | Left eye fundoscopy (week -3): Abnormal CS | Right eye fundoscopy (week -3): Normal | Right eye fundoscopy (week -3): Abnormal NCS | Right eye fundoscopy (week -3): Abnormal CS | Left eye fundoscopy (EOT): Normal | Left eye fundoscopy (EOT): Abnormal NCS | Left eye fundoscopy (EOT): Abnormal CS | Right eye fundoscopy (EOT): Normal | Right eye fundoscopy (EOT): Abnormal NCS | Right eye fundoscopy (EOT): Abnormal CS | |
| Oral Semaglutide | 848 | 657 | 86 | 845 | 659 | 86 | 783 | 599 | 83 | 780 | 601 | 81 |
| Placebo | 843 | 673 | 74 | 858 | 661 | 72 | 790 | 597 | 62 | 787 | 599 | 64 |
Change from baseline (week 0) in systolic and diastolic blood pressure measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window). (NCT02692716)
Timeframe: Week 0, End of treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Oral Semaglutide | -5 | -1 |
| Placebo | -2 | -2 |
Participants experiencing an event onset for each individual component of the expanded composite cardiovascular outcomes (defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospitalisation or heart failure requiring hospitalisation) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment. (NCT02692716)
Timeframe: Maximum treatment duration is dependent on event rates and is estimated to be no longer than 19 months + 5 weeks of follow-up period.
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Cardiovascular death | Non-fatal myocardial infarction | Non-fatal stroke | Unstable angina requiring hospitalisation | Heart failure requiring hospitalisation | |
| Oral Semaglutide | 15 | 37 | 12 | 11 | 21 |
| Placebo | 30 | 31 | 16 | 7 | 24 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | percentage (Mean) |
|---|---|
| Linagliptin 5 mg | 1.003 |
| Glimepiride 1-4 mg | 1.053 |
| Placebo | 0.981 |
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | Percentage (Geometric Mean) |
|---|---|
| Linagliptin 5 mg | 1.262 |
| Glimepiride 1-4 mg | 1.045 |
| Placebo | 1.009 |
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm
| Intervention | percentage (Geometric Mean) |
|---|---|
| Linagliptin 5 mg | 0.885 |
| Glimepiride 1-4 mg | 1.002 |
| Placebo | 1.002 |
Number of patients with any adverse events (NCT01703286)
Timeframe: up to 20 weeks
| Intervention | participants (Number) |
|---|---|
| Linagliptin 5 mg | 11 |
| Glimepiride 1-4 mg | 25 |
| Placebo | 14 |
| REP - Linagliptin 5 mg | 4 |
| REP - Glimepiride 1-4 mg | 7 |
| Rep - Placebo | 7 |
The change in 2-hour postprandial plasma glucose from baseline (Day 1) to Visit 8 (Week 16) was analyzed using a general linear model including treatment, and baseline HbA1c stratum (< 9% or ≥ 9%) as fixed factors, and the baseline 2-hour postprandial plasma glucose concentrations as a covariate. (NCT01652729)
Timeframe: Baseline to Week 16
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -59.57 |
| Active Comparator: Sitagliptin | -23.61 |
| Placebo Comparator: Placebo | -38.68 |
The change in body weight (kg) from baseline (Day 1) to Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | kg (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -1.12 |
| Active Comparator: Sitagliptin | -1.19 |
| Placebo Comparator: Placebo | 0.15 |
The change in fasting plasma glucose concentrations from baseline (Day 1) to Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -21.3 |
| Active Comparator: Sitagliptin | -11.3 |
| Placebo Comparator: Placebo | 9.6 |
Absolute change in HbA1c from baseline (Day 1, Visit 3) to Week 28/Study Termination (Visit 11). Hypothesis testing on the primary endpoint followed a serial gated procedure with all tests carried out at a 2-sided significance level of 0.05 to protect the family-wise error rate. These tests were conducted sequentially, and are presented in the statistical analysis section below in the order in which they were performed; each test was the gatekeeper of later tests. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | percentage of total hemoglobin (Least Squares Mean) |
|---|---|
| Experimental: Exenatide | -1.13 |
| Active Comparator: Sitagliptin | -0.75 |
| Placebo Comparator: Placebo | -0.40 |
Percentage of subjects achieving HbA1c target values of < 7.0% at Week 28/Study Termination. (NCT01652729)
Timeframe: Baseline to Week 28
| Intervention | percentage of subjects (Number) | |||
|---|---|---|---|---|
| Baseline Yes | Baseline No | Week 28 Yes | Week 28 No | |
| Active Comparator: Sitagliptin | 1.6 | 98.4 | 32.0 | 68.0 |
| Experimental: Exenatide | 3.3 | 96.7 | 43.1 | 56.9 |
| Placebo Comparator: Placebo | 3.3 | 96.7 | 24.6 | 75.4 |
(NCT01954771)
Timeframe: 12 weeks
| Intervention | percentage (Median) |
|---|---|
| Control Group | 6.9 |
| SMBG-4 Group | 6.7 |
| SMBG-7 Group | 6.6 |
The peak value:>16.7mmol/L(which may precipitate ketosis),nadir:≤2.8mmol/L(Severe hypoglycemia). (NCT01954771)
Timeframe: 12 weeks
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Peak at baseline | Nadir at baseline | Peak at endpoint | Nadir at endpoint | |
| Control Group | 8.86 | 6.87 | 8.74 | 6.32 |
| SMBG-4 Group | 8.72 | 6.05 | 8.00 | 6.55 |
| SMBG-7 Group | 8.80 | 6.15 | 8.68 | 6.44 |
Severe hypoglycemia is defined as glucose concentration of ≤2.8mmol/L (50 mg/dL). (NCT01954771)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline CGMS | End-point CGMS | SMBG | |
| Control Group | 4 | 3 | 1 |
| SMBG-4 Group | 3 | 1 | 0 |
| SMBG-7 Group | 7 | 3 | 1 |
A correlation coefficient of 0.5 is defined as large effect size.(Cohen Jacob.Statistical power analysis for the the behavioral sciences.2nd edition.Lawrence Erlbaum Associates.1988:80) (NCT01954771)
Timeframe: 12 weeks
| Intervention | mmol/L (Median) | |
|---|---|---|
| MBG from SMBG | MBG from CGMS at endpoint | |
| Control Group | 7.92 | 7.62 |
| SMBG-4 Group | 8.00 | 7.24 |
| SMBG-7 Group | 7.81 | 7.76 |
Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. (NCT00032487)
Timeframe: Post baseline time to the first major macrovascular event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 264 |
| Arm 2 | 235 |
New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. (NCT00032487)
Timeframe: Post baseline time to first event up to 82 months
| Intervention | participants (Number) |
|---|---|
| Arm 1 | 283 |
| Arm 2 | 312 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
52 reviews available for metformin and Diabetic Angiopathies
| Article | Year |
|---|---|
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Comb | 2021 |
The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis.
Topics: Aortic Aneurysm, Abdominal; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; H | 2021 |
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV I | 2017 |
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV I | 2017 |
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV I | 2017 |
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Pe | 2017 |
Diabetes medications and cardiovascular disease: at long last progress.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hy | 2018 |
Metformin therapy in diabetes: the role of cardioprotection.
Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2013 |
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.
Topics: Comorbidity; Comparative Effectiveness Research; Contraindications; Diabetic Angiopathies; Heart Fai | 2013 |
Use of non-insulin therapies for type 1 diabetes.
Topics: Allylamine; Animals; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochlorid | 2013 |
Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-B | 2014 |
Use of metformin in diseases of aging.
Topics: Aging; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administratio | 2014 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type | 2015 |
Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise T | 2016 |
Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.
Topics: C-Reactive Protein; Cardiovascular Diseases; Diabetic Angiopathies; Drug Therapy, Combination; Glyca | 2008 |
Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropat | 2008 |
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Co | 2009 |
Changing the treatment paradigm for type 2 diabetes.
Topics: Algorithms; Blood Glucose; Delivery of Health Care; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2009 |
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In | 2009 |
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Enzyme Inhi | 2009 |
Metformin: safety in cardiac patients.
Topics: Acidosis, Lactic; Diabetes Mellitus; Diabetic Angiopathies; Heart Failure; Humans; Hypoglycemic Agen | 2010 |
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglyce | 2011 |
Gestational diabetes: implications for cardiovascular health.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetes, Ge | 2012 |
Microvascular diseases: is a new era coming?
Topics: Diabetic Angiopathies; Hemorheology; Humans; Metformin; Microcirculation; Microvessels; Myocardial I | 2012 |
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metformin; Outcome Assessment, Health Care | 2012 |
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dip | 2012 |
Evolution of exenatide as a diabetes therapeutic.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2013 |
Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Topics: Aged; Blood Glucose; Body Mass Index; Comorbidity; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic | 2003 |
Microcirculation in insulin resistance and diabetes: more than just a complication.
Topics: Arterioles; Blood Glucose; Capillaries; Capillary Permeability; Cell Adhesion; Diabetes Mellitus; Di | 2003 |
Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Topics: Albuminuria; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemostasis; | 2003 |
Endothelial dysfunction, inflammation and diabetes.
Topics: Acarbose; Animals; Cardiovascular Agents; Diabetes Mellitus; Diabetic Angiopathies; Endothelium, Vas | 2004 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl | 2004 |
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies | 2005 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie | 2006 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
Diabetes care for patients with peripheral arterial disease.
Topics: Anesthesia; Blood Pressure; Contrast Media; Diabetic Angiopathies; Diabetic Foot; Glycated Hemoglobi | 2007 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Ang | 2007 |
Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
Topics: Benzamides; Biguanides; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Humans; | 2008 |
Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Topics: Animals; Atherosclerosis; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus | 2008 |
Metformin: effective and safe in renal disease?
Topics: Acidosis, Lactic; Animals; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiop | 2008 |
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combi | 2008 |
[The value of metformin in therapy of type 2 diabetes: effect on insulin resistance, diabetic control and cardiovascular risk factors].
Topics: Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 1994 |
Lessons from UK prospective diabetes study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Foot; Diabeti | 1995 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Metformin.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Met | 1997 |
Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypog | 1999 |
[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1999 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio | 1999 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2000 |
[The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H | 2002 |
[Identification and prevention of vascular risk. Significance of metformin].
Topics: Anthropometry; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; I | 1990 |
[Action of metformin on vascular risk factors in diabetes].
Topics: Animals; Diabetic Angiopathies; Humans; Insulin; Insulin Resistance; Lipids; Metformin; Microcircula | 1988 |
49 trials available for metformin and Diabetic Angiopathies
| Article | Year |
|---|---|
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellit | 2020 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.
Topics: Adolescent; Blood Vessels; Brachial Artery; Cardiovascular Diseases; Child; Diabetes Mellitus, Type | 2017 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as | 2018 |
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiovascular Diseases; Cardiovascular System; Diabe | 2019 |
High intensity interval training protects the heart during increased metabolic demand in patients with type 2 diabetes: a randomised controlled trial.
Topics: Aged; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet; Exercise Th | 2019 |
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Darbepoetin alfa; Diabetes Mellitus, Type 2; Diabetic | 2019 |
Serum uromodulin inversely associates with aortic stiffness in youth with type 1 diabetes: A brief report from EMERALD study.
Topics: Adolescent; Adult; Aorta; Biomarkers; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 1; Dia | 2019 |
Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Topics: Age Factors; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2014 |
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium-Binding Proteins; Cardiovascular System; Diabetes Me | 2014 |
Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial.
Topics: Adolescent; Atrial Function, Left; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Diabet | 2015 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Dia | 2014 |
Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 2014 |
Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arginine; Cell Adhesion Molecules; Coronary Artery Disease; Diabetes Mellit | 2015 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2015 |
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
Topics: Albuminuria; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2015 |
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.
Topics: Aged; Biomarkers; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus | 2015 |
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study.
Topics: Adult; Amino Acids; Amino Acids, Branched-Chain; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2016 |
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2017 |
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2017 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
10-year follow-up of intensive glucose control in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gl | 2008 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2009 |
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Gro
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D | 2009 |
Simulated physician learning intervention to improve safety and quality of diabetes care: a randomized trial.
Topics: Adult; Aged; Cholesterol, LDL; Computer Simulation; Coronary Disease; Diabetes Mellitus; Diabetes Me | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dr | 2009 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Di | 2009 |
[Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypo | 2009 |
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Cell Survival; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dia | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet | 2011 |
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Carbamates; Diabetes Mellitu | 2012 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2012 |
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
Topics: Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus; Diabetic Angiopathies; Female; Fol | 2013 |
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
Topics: Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus; Diabetic Angiopathies; Female; Fol | 2013 |
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
Topics: Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus; Diabetic Angiopathies; Female; Fol | 2013 |
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
Topics: Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus; Diabetic Angiopathies; Female; Fol | 2013 |
The Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Ang | 2003 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.
Topics: Blood Flow Velocity; Blood Pressure; Blood Volume; Coronary Circulation; Coronary Disease; Diabetes | 2004 |
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
Topics: Acetylcholine; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response | 2005 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
Topics: Adult; Capillaries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease | 2007 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Topics: Albuminuria; Asia; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Cholesterol; Diabe | 1993 |
Lessons from UK prospective diabetes study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Foot; Diabeti | 1995 |
The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholester | 1996 |
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diabetes Mellit | 1996 |
The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hype | 1996 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
[Metformin in the UKPDS study. Metabolic and vascular results].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic A | 1999 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Chromans; D | 2002 |
Platelet behaviour in non-insulin-dependent diabetes--influence of vascular complications, treatment and metabolic control.
Topics: Adenosine Diphosphate; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Epinephrin | 1986 |
90 other studies available for metformin and Diabetic Angiopathies
| Article | Year |
|---|---|
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Di | 2020 |
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Topics: Adult; Aged; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ang | 2020 |
Metformin Should Not Be Used to Treat Prediabetes.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dia | 2020 |
Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.
Topics: Age Factors; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cross-Sectional Studies; Diabete | 2021 |
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
Topics: Adamantane; Biomarkers; Blood Glucose; Carotid Arteries; Carotid Intima-Media Thickness; Case-Contro | 2017 |
Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Female; Follo | 2018 |
Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cohort St | 2019 |
Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Drug Therapy, | 2019 |
Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study.
Topics: Adult; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endotheli | 2018 |
Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway.
Topics: Animals; Autophagy; Capillary Permeability; Cells, Cultured; Diabetes Mellitus, Experimental; Diabet | 2019 |
Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.
Topics: Adipose Tissue; Blood Glucose; Body Mass Index; Brachial Artery; Carotid Arteries; Diabetes Mellitus | 2013 |
C-peptide activates AMPKα and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; C-Peptide; Cells, Cul | 2013 |
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Topics: Age Factors; Aged; Albuminuria; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes.
Topics: Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Diet | 2013 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Femal | 2014 |
Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Cell Transdifferentiation; Cells, Cultured; Diabetic | 2013 |
Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study.
Topics: Administration, Oral; Aged; Chi-Square Distribution; Comorbidity; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2013 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats.
Topics: Animals; Aorta; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Hypoglycemic Agents; Male; M | 2014 |
Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Drug Therapy, | 2014 |
Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diab | 2014 |
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Topics: Adolescent; Austria; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Ang | 2015 |
Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.
Topics: Adult; Aged; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; F | 2015 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Topics: Administration, Oral; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic A | 2015 |
Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopath | 2015 |
Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
Topics: Aged; Cholesterol, LDL; Cross-Sectional Studies; Delta-5 Fatty Acid Desaturase; Diabetes Mellitus, T | 2015 |
Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cell Movement; Diabetic Angiopathies; Drug Synergism; E | 2016 |
Identifying the independent effect of HbA
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Substitution; Female; Glycated Hemoglob | 2016 |
Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury.
Topics: Alkenes; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Gl | 2016 |
Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Cohort Studies; | 2017 |
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Topics: Administration, Oral; Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2017 |
Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Topics: Aged; Chi-Square Distribution; Computed Tomography Angiography; Cross-Sectional Studies; Diabetes Me | 2017 |
Quality of diabetes care among patients managed by teleconsultation.
Topics: Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angio | 2008 |
Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Topics: Adult; Case-Control Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2008 |
[United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Topics: Blood Glucose; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2008 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitu | 2009 |
Metformin usages in women with heart failure.
Topics: Contraindications; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Metfor | 2009 |
Type 2 diabetes: target HbA1c of about 7%.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Follow-Up Studies; Glycate | 2009 |
A summary of the ADVANCE Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progr | 2009 |
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.
Topics: Aged; Blood Pressure; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2010 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Ty | 2010 |
Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes.
Topics: Adult; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Ce | 2010 |
Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Ther | 2010 |
Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Dia | 2011 |
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Topics: Adult; Aged; Cause of Death; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypo | 2011 |
Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin; Metformin; M | 2011 |
Prevalence of diabetic retinopathy in Peruvian patients with type 2 diabetes: results of a hospital-based retinal telescreening program.
Topics: Aged; Blindness; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy | 2011 |
Highlights from the latest articles in diabetes pharmacogenomics.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2012 |
Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus | 2012 |
The role of combination therapy in type 2 diabetes in the post-ACCORD era.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; D | 2012 |
Metformin may not reduce cardiovascular risk or all-cause mortality.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metformin; Outcome Assessment, Health Care | 2013 |
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Admin | 2013 |
Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic An | 2013 |
[Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; H | 2002 |
[Islands cells are not activated quickly enough. Risk of obstruction of blood vessels].
Topics: Arteriosclerosis; Blood Glucose; Cyclohexanes; Diabetic Angiopathies; Drug Therapy, Combination; Hum | 2002 |
[Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; | 2003 |
Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents.
Topics: Blood Glucose; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2003 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus | 2004 |
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.
Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Restenosis; Databases, Factual; Diabe | 2004 |
Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fami | 2005 |
Determinants of subclinical diabetic heart disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Body Mass Index; Diabetes Complicati | 2005 |
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Topics: Aged; Cardiac Output, Low; Cohort Studies; Contraindications; Diabetes Mellitus; Diabetic Angiopathi | 2005 |
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2005 |
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2005 |
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2005 |
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2005 |
Insulin-sensitizers may protect against CHF.
Topics: Diabetic Angiopathies; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Thiazolidinediones | 2005 |
Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 2 | 2006 |
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Topics: Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combina | 2006 |
Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Case-Control Studies; Coronary Circulation; Coronary Disease; Diabete | 2007 |
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agen | 2006 |
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Metformin; Repr | 2007 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Me | 2007 |
Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy | 2008 |
Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Humans; Hypogl | 2008 |
Diabetes specialists keep ACCORD data in perspective.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycated | 2008 |
[The anti-atherosclerotic effect of metformin in the initial phases of diabetes mellitus in adults].
Topics: Adult; Arteriosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Drug Evaluation; Female; Humans; | 1980 |
[The use of metformin in ischemic cardiopathy].
Topics: Adult; Coronary Disease; Diabetic Angiopathies; Female; Humans; Male; Metformin; Middle Aged | 1980 |
Chorea in hyperglycemia.
Topics: Aged; Aged, 80 and over; Brain; Chorea; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gl | 1998 |
Contra-indications to metformin therapy are largely disregarded.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coronary Disease; Cross-Sectional Studies; Diabet | 1999 |
Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Follow-Up | 1999 |
Metformin and risk of cardiovascular disease.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Metformin; Randomized | 1999 |
Metformin improves vascular function in insulin-resistant rats.
Topics: Acetylcholine; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endotheliu | 2000 |
Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; A | 1999 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mell | 2000 |
Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.
Topics: Aged; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 2000 |
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.
Topics: Aged; Aspirin; Cerebral Angiography; Cranial Sinuses; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
Topics: Blood Coagulation; Cardiotonic Agents; Diabetic Angiopathies; Enzyme Activation; Factor XIII; Fibrin | 2002 |
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
Topics: Antigens; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fibrinolys | 1992 |
Letter: Coronary care for myocardial infarction in diabetics.
Topics: Biguanides; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diet Therapy; Humans; | 1974 |